Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715736 | 1.00 | BACE1 (0.35) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL2715243 | 1.00 | BACE1 (0.35) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL24036551 | 1.00 | BACE1 (0.35) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL2715732 | 1.00 | BACE1 (0.35) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL2714380 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL31136995 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL2714374 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL14831789 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL14831788 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 | |
| SCHEMBL2714378 | 0.88 | PDE2A (0.36) | BACE1PDE2AIDO1GAAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | BACE1 1991/4885PDE2A 447/4885IDO1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.